
KTTA Stock Forecast & Price Target
KTTA Analyst Ratings
Bulls say
Pasithea Therapeutics is a company with a strong potential for growth due to its focus on treatments for central nervous system disorders and other diseases. With its innovative approach in the fields of neuroscience and drug development, the company has a promising pipeline of treatments for various diseases, including Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Schizophrenia. The recent amendment to the company's protocol for its Phase 1/1b trial of PAS-004, which allows for a longer on-treatment window and a more detailed assessment of tumor measurements, de-risks the program and strengthens its potential in the market. Additionally, the company's Rare Disease Designation and potential for a Priority Review Voucher from the FDA provide potential upside for the company and its investors. Overall, Pasithea Therapeutics' focus on meeting unmet needs in the market, coupled with its promising pipeline, make it a strong investment opportunity for the future.
Bears say
Pasithea Therapeutics is currently focused on researching and developing treatments for CNS disorders and other diseases such as RASopathies and certain cancers. However, its amended Phase 1/1b NF1-PN protocol to broaden Part A and the risk factors mentioned suggest potential challenges and uncertainties in the company's drug development progress and its future profitability, which may negatively impact the stock's performance. Additionally, the company's reliance on securing adequate funding and potential dilutive capital raises could further dampen the outlook for the stock.
This aggregate rating is based on analysts' research of Pasithea Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.
KTTA Analyst Forecast & Price Prediction
Start investing in KTTA
Order type
Buy in
Order amount
Est. shares
0 shares